Literature DB >> 8040292

Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus.

M Amagai1, T Hashimoto, N Shimizu, T Nishikawa.   

Abstract

Pemphigus vulgaris (PV) is an autoimmune blistering disease, in which autoantibodies against PV antigen (PVA or Dsg3) play a pathogenic role in inducing blister formation. Bacterial fusion proteins of PVA failed to absorb pathogenic autoantibodies from PV patients' sera probably because they did not represent the proper conformation. Therefore, a chimeric protein, PVIg, consisting of the whole extracellular domain of PVA and the constant region of human IgG1, was produced in either in COS7 or in insect Sf9 eucaryotic cells. Both PVIg-COS7 and PVIg-Sf9 were recognized by all of the 35 PV sera tested, but not by any of 10 pemphigus foliaceus (PF), 16 Brazilian PF, 10 bullous pemphigoid, or five normal control sera. Incubation of PV patients' sera with PVIg-Sf9 removed heterogeneous autoantibodies and significantly reduced their immunofluorescence titers on normal human epidermis, although PVIg-Sf9 did not affect the titers of PF sera at all. Furthermore, PVIg-Sf9 absorbed pathogenic autoantibodies from patients' sera and prevented gross blister formation in a neonatal mouse model for pemphigus. These results indicate that this baculovirus product has the proper conformation of the authentic PVA and that its conformation is important in pathogenicity of pemphigus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040292      PMCID: PMC296282          DOI: 10.1172/JCI117349

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  40 in total

1.  Mapping the main immunogenic region and toxin-binding site of the nicotinic acetylcholine receptor.

Authors:  T Barkas; A Mauron; B Roth; C Alliod; S J Tzartos; M Ballivet
Journal:  Science       Date:  1987-01-02       Impact factor: 47.728

2.  Neonatal pemphigus vulgaris.

Authors:  P Merlob; A Metzker; B Hazaz; H Rogovin; S H Reisner
Journal:  Pediatrics       Date:  1986-12       Impact factor: 7.124

Review 3.  The antigenic structure of proteins: a reappraisal.

Authors:  D C Benjamin; J A Berzofsky; I J East; F R Gurd; C Hannum; S J Leach; E Margoliash; J G Michael; A Miller; E M Prager
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

4.  Correlation of pemphigoid and pemphigus antibody titres with activity of disease.

Authors:  W M Sams; R E Jordon
Journal:  Br J Dermatol       Date:  1971-01       Impact factor: 9.302

Review 5.  An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs.

Authors:  M Kozak
Journal:  Nucleic Acids Res       Date:  1987-10-26       Impact factor: 16.971

6.  Extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion.

Authors:  M Amagai; S Kàrpàti; V Klaus-Kovtun; M C Udey; J R Stanley
Journal:  J Invest Dermatol       Date:  1994-04       Impact factor: 8.551

7.  Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.

Authors:  G J Anhalt; R S Labib; J J Voorhees; T F Beals; L A Diaz
Journal:  N Engl J Med       Date:  1982-05-20       Impact factor: 91.245

8.  Distinction between epidermal antigens binding pemphigus vulgaris and pemphigus foliaceus autoantibodies.

Authors:  J R Stanley; L Koulu; C Thivolet
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

9.  Further analysis of pemphigus autoantibodies and their use in studies on the heterogeneity, structure, and function of desmosomes.

Authors:  J C Jones; K M Yokoo; R D Goldman
Journal:  J Cell Biol       Date:  1986-03       Impact factor: 10.539

10.  Anti-cell surface pemphigus autoantibody stimulates plasminogen activator activity of human epidermal cells. A mechanism for the loss of epidermal cohesion and blister formation.

Authors:  K Hashimoto; K M Shafran; P S Webber; G S Lazarus; K H Singer
Journal:  J Exp Med       Date:  1983-01-01       Impact factor: 14.307

View more
  54 in total

1.  Pemphigus vulgaris: the other half of the story.

Authors:  R S Kalish
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity.

Authors:  V T Nguyen; A Ndoye; S A Grando
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

3.  p38 MAPK activation is downstream of the loss of intercellular adhesion in pemphigus vulgaris.

Authors:  Xuming Mao; Yasuyo Sano; Jin Mo Park; Aimee S Payne
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

Review 4.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

5.  Update on the cloning of monoclonal anti-desmoglein antibodies from human pemphigus patients: implications for targeted therapy.

Authors:  John R Stanley; Ken Ishii; Don L Siegel; Aimee S Payne
Journal:  Vet Dermatol       Date:  2009-10       Impact factor: 1.589

6.  IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion.

Authors:  David Rafei; Ralf Müller; Norito Ishii; Maria Llamazares; Takashi Hashimoto; Michael Hertl; Rüdiger Eming
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

7.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 8.  The diagnosis and treatment of autoimmune blistering skin diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Dtsch Arztebl Int       Date:  2011-06-10       Impact factor: 5.594

9.  Development and characterization of desmoglein-3 specific T cells from patients with pemphigus vulgaris.

Authors:  M S Lin; S J Swartz; A Lopez; X Ding; M A Fernandez-Vina; P Stastny; J A Fairley; L A Diaz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

10.  Antibodies against desmoglein 3 (pemphigus vulgaris antigen) are present in sera from patients with paraneoplastic pemphigus and cause acantholysis in vivo in neonatal mice.

Authors:  M Amagai; T Nishikawa; H C Nousari; G J Anhalt; T Hashimoto
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.